FDA Gene Therapy Division Chief's Unexpected Resignation

The Director of the Office of Therapeutic Products (OTP) within the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), which oversees the review of cell and gene therapies, Vijay Kumar, has announced his resignation. Kumar's departure follows the resignations of former FDA Commissioner Marty Makary and former CBER Director Vinay Prasad, as well as the dismissal of Tracy Beth Hñeg, Director of the Center for Drug Evaluation and Research (CDER). Karim Mikhail, Acting Director of CBER, will temporarily oversee OTP to ensure regulatory continuity. However, the prolonged interim status of key positions raises concerns about potential review delays. Frequent changes in regulatory leadership, which determines the approval pathways for new drugs, pose a significant challenge for biotech companies, increasing uncertainty in their development strategies.

REGENXBIO's Accelerated Approval Path Shows Promise

The timing of this regulatory department change coincides with the approval applications of gene therapy developers, marking a crucial turning point. REGENXBIO (RGNX) is preparing for the approval of NAVSUNLI (clemidsogene lanparvovec-sngl), a gene therapy for Hunter syndrome (MPS II). After receiving a Complete Response Letter (CRL) in February 2026, the company successfully negotiated with the FDA to pursue an accelerated approval application based solely on existing data from the CAMPSIITE Phase 1/2 clinical trial, without the need for a new clinical trial. REGENXBIO held a Type A meeting in July and plans to resubmit the Biologics License Application (BLA) in the third quarter. This is expected to provide a strong foundation for the company to compete with JCR Pharmaceuticals' JR-141 and other enzyme replacement therapies (ERTs) that cross the blood-brain barrier in the approximately $1 billion Hunter syndrome market.

UniQure Secures Path for Huntington's Disease Therapy

UniQure (QURE), which is developing AMT-130, a gene therapy candidate for Huntington's Disease, has also benefited from regulatory flexibility. Initially, the FDA requested a sham surgery control arm for AMT-130. However, in June 2026, the FDA reversed its position and agreed to allow UniQure to submit a BLA for accelerated approval based solely on the three-year data from the existing Phase 1/2 clinical trial. UniQure aims to submit the BLA within the third quarter of this year and has also received favorable terms for the confirmatory trial, including the allowance of a standard treatment control arm. In the $1.5 billion Huntington's disease therapy market, AMT-130 is expected to gain a competitive advantage over Roche's tominersen (Phase 2) and Wave's WVE-003 (Phase 1b/2a) as the first gene therapy.

Atara and Pierre Fabre Find Regulatory Breakthrough

Atara Biotherapeutics (ATRA), which is developing Ebvallo (tabelecleucel) for the treatment of EBV-related diseases, has also reached a compromise with the FDA. Ebvallo received a CRL in January of this year due to concerns about the representativeness of the data from a single-arm Phase 3 trial (ALLELE). However, following a recent Type A meeting, the company has agreed to resubmit the BLA using historical controls. Atara had expanded its licensing agreement with its partner, Pierre Fabre, in November 2023, with a total value of $640 million (including a $30 million upfront payment and $100 million in milestone payments), paving the way for future financial milestones. Despite the departure of the regulatory chief, the FDA appears to be maintaining a proactive and flexible approach to reviewing therapies for rare diseases.

Why This Matters

The temporary change in leadership at the FDA's Office of Therapeutic Products (OTP) may create short-term uncertainty in the review timelines for rare diseases and advanced biopharmaceutical pipelines. However, in the medium to long term, the accelerated approval pathway secured by UniQure (uniQure) and REGENXBIO (REGENXBIO) is expected to become a standard practice across the industry. In particular, UniQure's Huntington's disease therapy AMT-130 (Phase 1/2) and REGENXBIO's Hunter syndrome therapy NAVSUNLI (BLA resubmission planned) have obtained waivers for control arm clinical trials, accelerating their entry into the $1.5 billion and $1 billion niche markets by two to three years compared to initial expectations. This will be a key factor in widening the gap with later entrants such as Roche's tominersen and JCR Pharmaceuticals' JR-141. As demonstrated by Atara's (Atara) Ebvallo case, regulatory flexibility in allowing historical controls will lead to reduced clinical costs and increased probability of new drug launches, thereby maximizing the capital efficiency of global biotech companies.